INSMED INC (INSM)       21.79  +0.2 (+0.93%)

21.79  +0.2 (+0.93%)

US4576693075 - Common Stock

INSMED INC21.79

NASDAQ:INSM (2/6/2023, 12:10:31 PM)+0.2 (+0.93%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-27 2022-10-27/bmo Earnings (Next) 02-15 2023-02-15/amc
Ins Owners 1.07% Inst Owners 94.35%
Market Cap 2.95B Shares 135.48M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 84.21
IPO 02-15 1991-02-15

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INSM Daily chart

Company Profile

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 613 full-time employees. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Company Info

INSMED INC

700 Us Highway 202/206

Bridgewater NEW JERSEY 08807

P: 19089779900.0

CEO: William H. Lewis

Employees: 613

Website: https://insmed.com/

INSM News

News Image11 days ago - Emerald Asset Management PA, LLCAnalysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment ForumNews Image14 days ago - Market News VideoInsmed Breaks Above 200-Day Moving Average - Bullish for INSMNews Imagea month ago - Insmed IncorporatedInsmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment...

News Imagea month ago - Insmed IncorporatedInsmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image2 months ago - Insmed IncorporatedInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

News Image2 months ago - Insmed IncorporatedInsmed To Present at the Nasdaq 47th Investor Conference

/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

INSM Twits

Here you can normally see the latest stock twits on INSM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example